Experimental pill shows early promise for painful skin condition
NCT ID NCT05997277
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This pilot study tested the drug deucravacitinib against a placebo in people with moderate-to-severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. Only 7 people enrolled before the study was stopped early. The goal was to see if the drug could reduce inflammatory lesions over 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Deucravacitinib (a targeted oral medication that blocks a specific immune pathway)
What this could lead to
If it works, this could point toward a new oral treatment option for hidradenitis suppurativa, a painful skin condition.
What could go wrong
This is a very small, early pilot study that was terminated early with only 7 participants, so results are limited and may not be reliable. The drug may not prove effective or safe in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States